News

MAX Surgical Specialty Management Gains $77 Million Credit Boost

MAX Surgical Specialty Management Gains $77 Million Credit Boost

MAX Surgical Specialty Management Secures Major Financing

MAX Surgical Specialty Management, a leader in oral and maxillofacial surgery (OMS), has recently closed on a substantial $77 million senior credit facility. This financing is provided by Freeport Financial Partners, LLC, and will play a crucial role in facilitating the company's growth across the Northeast. It aims to empower MAX to forge new partnerships with top OMS practices in the region.

Strategic Growth and Partnerships

Mark Censoprano, Co-CEO of MAX, emphasized the importance of community connections in their expansion strategy. "Staying close to the communities we serve is at the heart of our partnership strategy," he stated. This injection of capital is designed to strategically enhance their presence across Northeast regions, ensuring that partnerships align with the community's healthcare needs.

The Latest Collaboration

In an exciting development, MAX has formed a partnership with Rothman and Kim Oral & Maxillofacial Surgery, a renowned practice in the Philadelphia area. Founded over 25 years ago by Drs. Marc Rothman and David Kim, this partnership marks a pivotal addition to MAX's network, having already established two locations.

Strengthening the Network

This partnership comes shortly after MAX welcomed Oral and Maxillofacial Surgery of Westfield into its network, led by Dr. Ronen Gold, renowned for his patient-first approach. Such collaborations augment MAX's presence in New Jersey and reinforce its reputation as a prominent OMS support platform, leading advancements in patient care across the region.

Rapid Expansion and Growth

MAX's network has seen remarkable growth since early 2024, adding 14 new practice locations and 17 surgeons to its roster in several states including New Jersey, New York, and Pennsylvania. This growth reflects a strategic focus on expanding their operational reach, nearly doubling their workforce to over 300 professionals. Such rapid expansion showcases MAX's forward-thinking approach to enhancing healthcare delivery.

Commitment to Excellence

According to Matt Gerdes, Managing Director at Freeport Financial Partners, this investment is a testament to the confidence in MAX's operational excellence and robust leadership team. He noted, "MAX's strong fundamentals and long-term value creation potential presented a compelling opportunity." This recognition underscores the significant potential that the company holds within the healthcare landscape.

Exceptional Leadership

Dr. Jason M. Auerbach, Founder and Co-CEO, also shared insights on the company’s mission. He highlighted that recruiting elite oral and maxillofacial surgeons who strive for excellence in patient care is a fundamental goal for MAX. The collaboration with established practices enhances this vision.

A Broad Reach for Quality Care

MAX now encompasses a concentrated network of OMS practices, which offers distinct advantages such as regional insights and strengthened relationships. This broader reach is significant to its operational strategy, ensuring high quality and accessible care to more patients.

About MAX Surgical Specialty Management

Established in 2022, MAX was developed to create a leading management services organization for oral and maxillofacial surgery in the Northeast. With a clear focus on surgeon autonomy and clinical excellence, MAX continually supports practices in New Jersey, New York, Pennsylvania, Vermont, and Connecticut. The organization is dedicated to empowering surgeons with resources and advancing the specialty through collaborative efforts.

Key Collaborators

MAX benefits from the backing of MedEquity Capital, RF Investment Partners, and Kian Capital, each playing a vital role in its strategic ambitions. Together, they represent a strong investment in the future growth and scalability of MAX's network.

Conclusion

With its recent financing and partnerships, MAX Surgical Specialty Management is positioned to expand its footprint significantly in the oral and maxillofacial surgery market. By fostering relationships that enhance patient care and leveraging its operational strengths, MAX is not only upholding its reputation but also paving the way forward for advancements in the field.

Frequently Asked Questions

What is MAX Surgical Specialty Management known for?

MAX focuses on providing management services for oral and maxillofacial surgery, promoting clinical excellence and surgeon autonomy.

How much financing did MAX recently secure?

MAX secured a $77 million senior credit facility to support its growth and partnership strategies.

Who are MAX's notable partners?

MAX has partnered with established practices like Rothman and Kim Oral & Maxillofacial Surgery and Oral and Maxillofacial Surgery of Westfield.

In which regions does MAX operate?

MAX operates primarily in the Northeast, including states like New Jersey, New York, and Pennsylvania.

What is the mission of MAX Surgical Specialty Management?

The mission of MAX is to provide exceptional support to oral and maxillofacial surgeons while focusing on advancing patient care and leading industry innovations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Mavis Discount Tire Launches New Premier Facility in Florida

Updated Category News Views 119

Mavis Discount Tire Launches New Premier Facility in Florida Mavis Discount Tire, known for its superior automotive service and commitment to customer satisfaction, is thrilled to announce the opening of its latest facility. The new store location, situated at 5260 US Hwy 1, is designed to cater to the needs of the Harris Point and nearby community. Expanding Presence and...

Continue Reading
Electra Therapeutics Secures Major Funding for Innovative Cancer Therapies

Updated Category News Views 250

Electra Therapeutics Makes a Significant Funding Leap Electra Therapeutics has recently announced a remarkable $183 million Series C financing round aimed at enhancing its pipeline of innovative therapies designed to tackle immune disorders and various cancers. This substantial funding is not only indicative of the investors' confidence in the company but also emphasizes...

Continue Reading
Transforming Business Culture: A Call for Excellence

Updated Category News Views 92

Transforming Business Culture: A Call for Excellence In today's dynamic corporate landscape, where competition is fierce and expectations are high, settling for mediocrity is not an option. Bestselling author and leadership expert John Rossman has articulated this challenge in his new work, “The Pig, The Lipstick and the Three Pillars of Champions: Reclaiming Your...

Continue Reading
Quantum BioPharma Offers $7 Million Reward for Insider Tips

Updated Category News Views 130

Quantum BioPharma Announces Whistleblower Cash Reward Quantum BioPharma Ltd. (NASDAQ: QNTM) is making significant waves in the biopharmaceutical industry with its innovative strategy designed to combat stock manipulation. The company has launched a whistleblower policy that offers a remarkable cash reward of up to USD $7 million to those who provide concrete evidence...

Continue Reading
Evaxion Biotech Prepares for Upcoming Quarterly Earnings Call

Updated Category News Views 142

Anticipating Evaxion Biotech's Quarterly Earnings Evaxion Biotech (NASDAQ: EVAX) is gearing up to unveil its quarterly earnings report, creating a buzz of anticipation among investors. The company aims to share essential financial details that could influence stock performance and investor sentiment. Expected Earnings Performance Analyst Predictions Analysts predict that...

Continue Reading